Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 81
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products,...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell